Data Science and Artificial Intelligence - Turning Data into Knowledge
Our collaboration with BenevolentAI uses machine learning and AI to discover potential new drugs targets for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF). By combining our disease area expertise and large, diverse data sets with BenevolentAI’s leading AI and machine learning capabilities we hope to improve our understanding of complex disease biology and more quickly identify new drug targets. To find out more about how data science and AI have the potential to transform drug discovery and development visit: https://www.astrazeneca.com/what-scie.... ---------------------------------------- Global site: https://www.astrazeneca.com/ Careers site: https://careers.astrazeneca.com/ Follow us: Twitter: / astrazeneca LinkedIn: / astrazeneca Instagram: / astrazeneca Facebook: / astrazeneca
Early Talent at AstraZeneca: Shaping the Future Together
Jim Weatherall, VP of Data Science and AI
The Discovery Centre (DISC): Unlocking the power of science
Chronic kidney disease: a patient story
Machine learning and AI across discovery sciences
Title: Global Operations at AstraZeneca – Change a Life
Living with Blood Cancer: Tania’s Story
What is COVID-19, and how can it be prevented and treated?
The potential of T-cell receptor therapies
AI and the Big Difference in Health Care
In Vivo Cell Therapy
The AstraZeneca story
AstraZeneca IT – Follow the Sun
Collaborating with Mila to maximize the potential of AI
Global Procurement. Speed, Savings, Sustainability
Cell therapy uncovered: advancing cell therapy in the clinic
Biomanufacturing a COVID-19 vector vaccine
Realising the Full Curative Potential of Cell Therapy
Epigenetics: the next revolution in cancer treatments
